Primary lateral sclerosis (PLS) is a motor neuron disease that occurs when the nerve cells in muscles slowly deteriorate.

OBJECTIVE To describe the clinical, neurophysiological, and MRI findings in 10 patients with primary lateral sclerosis (PLS). RESULTS The course of the disease was very slowly progressive. Spasticity ...

HB-adMSCs is under clinical development by Hope Biosciences and currently in Phase I for Primary Lateral Sclerosis. According to GlobalData, Phase I drugs for Primary Lateral Sclerosis does not have ...

Primary Lateral Sclerosis — Unicorn, Dragon or Other Mythological Beast? Lauren Elman, M.D., associate professor of neurology at the Hospital of the University of Pennsylvania and Penn Medicine, ...

Methods Cohort recruited via a specialist, multidisciplinary clinic. Patients were categorised into four clinical phenotypes (ALS, flail arm, flail leg and primary lateral sclerosis) according to site ...

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.

Motor neuron disease usually refers to amyotrophic lateral sclerosis, but it can also refer to other kind of neurodegenerative disease that affect the motor neurons, such as progressive primary ...

DNL343 For The Treatment Of Patients With Amyotrophic Lateral Sclerosis As I stated directly above, Denali Therapeutics reported that it had failed to meet the primary endpoint of the phase 2/3 ...

Compared to placebo, the study did not meet the primary endpoint of efficacy in slowing disease progression. The primary endpoint was evaluated as a change in disease severity over time as ...

“pure” progressive muscular atrophy and primary lateral sclerosis, flail arm or leg, and those that rapidly progress) Ability to predict regional involvement and the pattern of spread in advance of ...